Blood-based biomarkers in mild behavioral impairment: an updated overview

Frontiers in Neurology, Journal Year: 2025, Volume and Issue: 16

Published: Feb. 6, 2025

Identifying individuals at-risk for dementia is one of the critical objectives current research efforts, highlighting need simple, cost-effective, and minimally invasive biomarkers. Mild behavioral impairment (MBI), characterized by emergence persistent neuropsychiatric manifestations in older adults, has attracted increasing attention as a potential early indicator cognitive decline dementia. A growing number studies have recently begun to explore relationship between MBI several blood-based biomarkers associated with Alzheimer's disease (AD) pathology, neurodegeneration, well systemic metabolic inflammatory dysregulation. In this context, been lower plasma Aβ42/Αβ40 ratio, higher phosphorylated tau at threonine 181 (p-tau181), increased neurofilament light chain (NfL) levels, disturbances markers, including homocysteine, insulin ferritin, suggesting multifaceted neurobiological basis syndrome. These findings offer insights into underlying pathophysiology MBI, connection symptoms progression AD. narrative review, we aim summarize critically discuss emerging literature evidence linking biomarkers, hoping shed more on MBI's pathophysiology, its AD-related neurobiology, practical utility predicting impairment, guiding interventions managing risk

Language: Английский

The Advancements of Marine Natural Products in the Treatment of Alzheimer’s Disease: A Study Based on Cell and Animal Experiments

Marine Drugs, Journal Year: 2025, Volume and Issue: 23(3), P. 91 - 91

Published: Feb. 20, 2025

As life expectancy rises and the aging population grows, Alzheimer’s disease (AD) has become a significant global health concern. AD is complex neurodegenerative disorder with an unclear etiology. Current hypotheses primarily focus on β-amyloid (Aβ) aggregation, tau protein hyperphosphorylation, neuroinflammation as key pathological processes. Given limited efficacy of existing therapeutic strategies, there urgent need to explore novel treatment options. Marine natural products have garnered attention due their unique chemical structures diverse bioactivities, demonstrating potential for multi-target interventions in AD. This review systematically summarizes roles marine-derived compounds, including polysaccharides, carotenoids, polyphenols, modulating Aβ mitigating pathology, regulating gut–brain axis dysfunction. Furthermore, challenges current research are discussed, emphasis improving blood–brain barrier permeability optimizing drug delivery systems facilitate clinical translation.

Language: Английский